{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:51:55Z","timestamp":1761979915907,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jasc.2020.07.133","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T03:35:36Z","timestamp":1595993736000},"page":"602-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?"],"prefix":"10.1016","volume":"9","author":[{"given":"R. Marshall","family":"Austin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Onisko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2020.07.133_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2020.07.133_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP Risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2020.07.133_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines","volume":"24","author":"Egemen","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2020.07.133_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"Massad","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jasc.2020.07.133_bib5","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society [published online ahead of print, 2020 Jul 30]","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jasc.2020.07.133_bib6","first-page":"e111","article-title":"Practice Bulletin No. 168: cervical cancer screening and prevention","volume":"128","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jasc.2020.07.133_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cervical cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jasc.2020.07.133_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1479-828X.2010.01170.x","article-title":"Consequences in women of participating in a study of the natural history of cervical epithelial neoplasia 3","volume":"50","author":"McCredie","year":"2010","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jasc.2020.07.133_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/ijc.29053","article-title":"Sensitivity, effect and over-diagnosis in screening for cancers with detectable pre-invasive phase","volume":"136","author":"Hakama","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jasc.2020.07.133_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jasc.2018.07.003","article-title":"HPV screening, invasive cervical cancer and screening policy in Australia","volume":"7","author":"Cox","year":"2018","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2020.07.133_bib11","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systemic review and meta-analysis","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jasc.2020.07.133_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/bjc.1996.441","article-title":"Forty years of repeated screening: the significance of carcinoma in situ","volume":"74","author":"Morrison","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2020.07.133_bib13","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/ijc.27850","article-title":"The HPV test has similar sensitivity but more overdiagnosis than the Pap test\u2014a randomized health services study on cervical cancer screening in Finland","volume":"132","author":"Malila","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jasc.2020.07.133_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/AOG.0b013e3181e3e719","article-title":"The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer","volume":"116","author":"Castle","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jasc.2020.07.133_bib15","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1055-9965.EPI-10-0131","article-title":"HPV Prevalence Italian Working Group. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy","volume":"19","author":"Carozzi","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jasc.2020.07.133_bib16","first-page":"755","article-title":"International incidence rates of invasive cervical cancer after introduction of cytologic screening","volume":"8","author":"Gustaffson","year":"1997","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jasc.2020.07.133_bib17","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1136\/bmj.e900","article-title":"Screening and cervical cancer cure: population-based cohort study","volume":"344","author":"Andrae","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jasc.2020.07.133_bib18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2016.290","article-title":"Impact of cervical screening on cervical mortality; estimation using stage-specific results from a nested case-control study","volume":"115","author":"Landy","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2020.07.133_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jasc.2020.07.133_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ajcp\/aqy114","article-title":"Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting","volume":"150","author":"Austin","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2020.07.133_bib21","first-page":"aqaa074","article-title":"Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer","volume":"152","author":"Kaufman","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2020.07.133_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2017.19872","article-title":"Screening for cervical cancer in primary care: a decision analysis for the US preventive services task force","volume":"320","author":"Kim","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jasc.2020.07.133_bib23","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/sim.7380","article-title":"Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records","volume":"36","author":"Cheung","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jasc.2020.07.133_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/LGT.0b013e3182616241","article-title":"Screening for cervical cancer: a modelling study for the U.S. Preventive Services Task Force","volume":"17","author":"Kulasingam","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2020.07.133_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jasc.2020.07.133_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/AOG.0000000000000632","article-title":"Increased cervical cancer risk associated with screening at longer intervals","volume":"125","author":"Kinney","year":"2015","journal-title":"Obstet Gynecol"},{"year":"2011","series-title":"Screening for Cervical Cancer. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Syntheses, No. 86. Oregon Evidence-based Practice Center. AHRQ Publication No. 11-05156-EF-1","author":"Vesco","key":"10.1016\/j.jasc.2020.07.133_bib27"},{"key":"10.1016\/j.jasc.2020.07.133_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.5858\/134.5.744","article-title":"The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool","volume":"134","author":"Austin","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2020.07.133_bib29","series-title":"Foundations of Biomedical Knowledge Representations, Methods and Applications, Lecture Notes on Artificial Intelligence","first-page":"207","article-title":"Dynamic Bayesian network for cervical cancer screening","author":"Onisko","year":"2015"},{"key":"10.1016\/j.jasc.2020.07.133_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jasc.2015.05.001","article-title":"Increased cervical cancer risk associated with extended screening intervals after negative human papilloma virus (HPV) test results: Bayesian risk estimates using the Pittsburgh Cervical Cancer Screening Model","volume":"5","author":"Austin","year":"2016","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2020.07.133_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/2153-3539.197191","article-title":"How to interpret the results of medical time series data analysis: classical statistical approaches versus dynamic Bayesian network modeling","volume":"7","author":"Onisko","year":"2016","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.jasc.2020.07.133_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/dc.23993","article-title":"Application of Bayesian network modeling to pathology informatics","volume":"47","author":"Onisko","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2020.07.133_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/jpi.jpi_66_19","article-title":"Individualized risk assessment for cervical squamous neoplasia","volume":"11","author":"Farchoukh","year":"2020","journal-title":"J Pathol Inform"},{"key":"10.1016\/j.jasc.2020.07.133_bib34","first-page":"59","article-title":"Personalized medicine and cervical screening: development of individualized quantitative risk assessments for cervical adenocarcinoma and adenocarcinoma-in-situ","volume":"32","author":"Jones","year":"2019","journal-title":"Mod Pathol"},{"year":"2012","series-title":"The Theory That Would Not Die: How Bayes Rule Cracked the Enigma Code, Hunted Down Russian Submarines, and Emerged Triumphant from Two Centuries of Controversy","author":"McGrayne","key":"10.1016\/j.jasc.2020.07.133_bib35"},{"key":"10.1016\/j.jasc.2020.07.133_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1099-1360(199603)5:1<39::AID-MCDA109>3.0.CO;2-Q","article-title":"Multi-attribute decision support in the event of a nuclear accident","volume":"5","author":"French","year":"1996","journal-title":"J Multi Criteria Decis Anal"},{"key":"10.1016\/j.jasc.2020.07.133_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.nucengdes.2015.05.010","article-title":"Pilot study of dynamic Bayesian networks approach for fault diagnostics and accident progression prediction in HTR-P","volume":"291","author":"Zhao","year":"2015","journal-title":"Nucl Eng Des"},{"author":"Chrisman","key":"10.1016\/j.jasc.2020.07.133_bib38"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294520302623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294520302623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:47:02Z","timestamp":1761979622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294520302623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2213294520302623"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2020.07.133","relation":{},"ISSN":["2213-2945"],"issn-type":[{"type":"print","value":"2213-2945"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2020.07.133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}